A new analysis shows attempts by drugmakers to raise prices are being wiped out in negotiations with managers of drug insurance benefits like Express Scripts Holding Co. and CVS Health Corp.
Education reform groups are struggling to raise money locally, even as Indiana is recognized as one of the friendliest in the nation for school reform ideas.
IBJ’s front-page article flies directly in the face of these business arguments. As quoted, the city of Indianapolis, which already has anti-discrimination protections for LGBT, has seen reductions in both high-tech jobs and highly educated workers.
The Monument Circle church suffered a setback in May after a judge threw out most of the case against the banking giant but give it a chance to refile most of its claims.
The experimental medicine, called romosozumab, showed better results than Eli Lilly and Co.’s Forteo after 12 months, Amgen and UCB said in a joint statement Wednesday.
The Indiana University School of Medicine has been selected to lead a five-year, $12 million national research project to develop new treatments for inherited cancers and related developmental disorders. The grant comes from the National Cancer Institute. Dr. Wade Clapp, chairman of the department of pediatrics at the IU medical school will serve as the […]
Jubilant Indianapolis Public School Board members on Thursday night hailed an aggressive strategic plan and $12 million in pay raises for teachers as a potential turning point for the city’s schools.
The Indianapolis Monumental Marathon is one of seven U.S. marathons that have teamed with Virginia-based media conglomerate Gannett Co. to form a nationwide marathon series.
Calibrium LLC and MB2 LLC, both based in Carmel, have agreed to be sold for undisclosed amounts. They were developing diabetes drugs discovered by the research team of Richard DiMarchi, a chemistry professor at Indiana University.
Eli Lilly and Co. won a court ruling that will keep generic versions of the chemotherapy drug Alimta off the U.S. market until a patent expires in 2022.
Eli Lilly and Co. didn’t win approval for a new drug last week. But its latest study of an existing diabetes drug could create a blockbuster in its own right—adding as much as $1 billion a year to the coffers of the Indianapolis-based drugmaker.
While businesses consider many factors before choosing where to locate, economic development experts say a community’s openness to lesbian, gay, bisexual and transgender individuals increasingly is one of them.
Lilly’s stock had its biggest intraday gain since 2009 Thursday after it announced trial results that showed Jardiance lowered the risk of heart attacks, stroke and death in a large trial of adults with type 2 diabetes.
The new head of research at the Indiana University School of Medicine thinks the institution is missing out on the more than $6 billion spent each year in the United States on clinical trials.
Previous Top Honorees are not eligible for nomination. Remaining honorees are eligible. 2019 Not-For-Profit/Government Todd Davis, Hendricks Regional Health Steve Herriford, University of Indianapolis Peter Williams, Butler University – Top Honoree Private Company — Under $100M Joe Gadell, GadellNet Consulting Services Curt Knapp, Perq – Top Honoree Alan Pyrz, eGov Strategies Private Company — Over […]
